Published May 22, 2020 | Version v1
Journal article Open

Gastritis crónica y cáncer gástrico

Authors/Creators

  • 1. Laboratorio de Inmunología Experimental, Facultad de Medicina de la Benemérita Universidad Autónoma de Puebla, Calle 13 Sur 2702, Los Volcanes, 72420, Puebla, México

Description

RESUMEN

El cáncer gástrico es la tercera causa de mortalidad y la quinta de incidencia por cáncer en todo el mundo. De igual forma, la gastritis crónica es una enfermedad con una alta morbilidad y mortalidad a nivel mundial, cuyo principal factor de riesgo es la bacteria Helicobacter pylori. El diagnóstico de esta última se lleva a cabo mediante endoscopia y confirmación histológica, y ya que suele ser asintomática corre el riesgo de pasar a una metaplasia, displasía y cáncer. Una de las principales estrategias para la prevención de ambas enfermedades es la erradicación de H. pylori.

 

ABSTRACT

Gastric cancer is the third leading cause of mortality and the fifth leading cause of cancer worldwide. Similarly, chronic gastritis is a disease with high morbidity and mortality worldwide, whose main risk factor is Helicobacter pylori bacteria. The latter is diagnosed by endoscopy and histological confirmation, and since it is usually asymptomatic, there is a risk of metaplasia, dysplasia and cancer. One of the main strategies for the prevention of both diseases is the eradication of H. pylori.

Files

6 Galicia-Zamalloa y Diaz Y Orea 2020.pdf

Files (1.2 MB)

Name Size
md5:ba76525c02a373282ec9d0c5d0d8860d
1.2 MB Preview Download

Additional details

Identifiers

ISSN
2594-0627
URL
https://www.aytbuap.mx/aytbuap-518/gastritis-cr%C3%B3nica-y-c%C3%A1ncer-g%C3%A1strico
URL
https://eoi.citefactor.org/10.11235/BUAP.05.18.04

Related works

Is identical to
Journal article: https://repositorioinstitucional.buap.mx/handle/20.500.12371/9401 (URL)

References

  • Pizzi M, Saraggi D, Fassan M, et al. Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori- associated gastritis. Dig Dis. 2014;32:265-74
  • Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43(Suppl 4):S373-84.
  • Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014; 20:5191-204.
  • Møller H, Heseltine E, Vainio H, Working group report on schistosomes, liver flukes and Helicobacter pylori. Meeting held at IARC, LYON, 7-14 june 1994. Int. J. Cáncer, 1995;(60):587-89.
  • Azer SA, Hossein A. "Gastritis." StatPearls, StatPearls Publishing, 2020.
  • Schindler R. Chronic gastritis. Klin Wochenschr 1966;44:601-12.
  • Siurala M. The story of gastritis. Scand J Gastroenterol (Suppl. 1991;186):1-3.
  • Telaranta-Keerie A, Kara R, Paloheimo L, Harkonen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol. 2010;45:1036-41.
  • Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;(20):1161-81.
  • Cruveilhier J. Considérations générales sur les ulcérations folliculaires de l'estomac. Atlas d'Anatomie Pathologique, Vol II. Paris: Bailliére JB, 1842.
  • Dale, HH. Adventures in physiology. Pergamon Press; London: 1953.
  • Cheli R, Perasso A, Giacosa A, Gastritis. A Critical Review. Foreword by BI Hirschowitz. Berlin, Heidelberg: Springer- Verlag, 1987.
  • Schindler R. Gastritis. London: Grune & Stratton, 1947.
  • Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;323:1311-15.
  • Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50:657- 67.
  • Sipponen P. Chronic gastritis in former times and now. Helicobacter. 2007 Nov;12 Suppl 2:16-21.
  • Kekki M. (ed.) Gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol 1991;26 [1] (Suppl. 186):1-150.
  • Cave DR. Transmission and epidemiology of Helicobacter pylori. Am J Med 1996;(100):12S-17S; discussion 17S-18S.
  • Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;(56):631-6.
  • Alarcón-Millán J, Fernández-Tilapa G, Cortés-Malagón EM, et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern Mexico with Chronic Gastritis. (2016).
  • Chihu L, Ayala G, Mohar A, et al. 2005. Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from mexican adults with clinical outcome. J. Chemother. 2005, 17:270-6.
  • Paniagua GL, Monroy E, Rodríguez R, et al. Frequency of vacA, cagA and babA2 virulence markers in Helicobacter pylori strains isolated from mexican patients with chronic gastritis. Ann. Clin. Microb. 2009;8, 1-6.
  • Hunt RH, Xiao SD, Megraud F. Helicobacter pylori in developing countries. World Gastroenterology Organization Global Guideline. J Gastrointestin Liver Dis. 2010; 299-304.
  • Huang Y, Wang Q, Cheng D, et al. Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter pylori. Frontiers in Cellular and Infection Microbiology. 2016;6:159.
  • Malfertheiner P, Megraud F, Morain C, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-64.
  • Camargo MC, Lazcano-Ponce E, Torres J. Determinants of Helicobacter pylori seroprevalence in Mexican adolescents. Helicobacter., 2004; 9:106-14.
  • Maaroos HI, Rago T, Sipponen P, Siurala M. Helicobacter pylori and gastritis in children with abdominal complaints. Scand J Gastroenterol 1991;26:95-9.
  • Maaroos HI, Kekki M, Villako K, Sipponen P, Tamm A, Sadeniemi L. The occurrence and extent of Helicobacter pylori colonization and antral and body gastritis profiles in an Estonian population sample. Scand J Gastroenterol 1990;25: 1010-17.
  • Eusebi LH et al. Gastric cancer prevention strategies: A global perspective. Journal of gastroenterology and hepatology, 10.1111/jgh.15037. 17 Mar. 2020.
  • Driscoll LJ, Brown HE, Harris RB, Oren E. Population Knowledge, Attitude, and Practice Regarding Helicobacter pylori Transmission and Outcomes: A Literature Review. Front. Public Health. 2017; 5:144.
  • Zhang Y, Zhou A, et al. Exploratory Factor Analysis for Validating traditional Chinese Syndrome Patters of Chronic Atrophic Gastritis. Evid Based Complement Alternat Med. 2016; 2016: 6872890.
  • Abreu L. Gastroenterología: endoscopia diagnóstica y terapéutica. Gastritis. Segunda Edición. Madrid. Médica Panamericana. 2007;165-72.
  • Ihamaki T, Kekki M, Sipponen P, Siurala M. The sequelae and course of chronic gastritis during a 30 to 34 year bioptic follow- up study. Scand J Gastroenterol 1985;20:485- 91.
  • Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long- term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastro- enterol 1996;31:546- 50.
  • Villako K, Kekki M, Maaroos HI, Sipponen P, Tammur R, Tamm A, et al. A 12- year follow-up study of chronic gastritis and Helicobacter pylori in a population-based random sample. Scand J Gastroenterol 1995;30:964-7.
  • de Souza CRT, Almeida MCA, Khayat AS, da Silva EL, Soares PC, Chaves LC, Burbano RMR. Association between Helicobacter pylori, Epstein-Barr virus, human papillomavirus and gastric adenocarcinomas. World J. Gastroenterol. 2018;24(43):4928-38.
  • Araya J, Villaseca M, Roa I, et al. Helicobacter pylori y gastritis crónica: relación entre infección y actividad inflamatoria en población de alto riesgo de cáncer gástrico. Rev Méd Chile 2013;128:125-29.
  • Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut. 2015;64(10):1650-68.
  • Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 2003;17:99-109.
  • Silveira PA, Wilson WE, Esteban LM, et al. Identification of the Gasa3 and Gasa4 autoimmune gastritis susceptibility genes using congenic mice and partitioned, segregative and interaction analyses. Immunogenetics. 2001;53(9):741-50.
  • Baxter AG, Jordan MA, Silveira PA, Wilson WE, Van Driel IR. Genetic control of susceptibility to autoimmune gastritis. Int Rev Immunol. 2005;24(1-2):55-62.
  • Park YH, Kim N. Review of Atrophic Gastritis and Intestinal Metaplasia as a Premalignant Lesion of Gastric Cancer. Journal of Cancer Prevention. 2015;20(1):25- 40.
  • Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007;(42):2-10.
  • Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment. Pharmacol Ther. 2002;(16):3-15.
  • Bosques-Padilla FJ, Tijerina-Menchaca R, Pérez-Pérez GI, et al. Comparison of Helicobacter pylori prevalence in symptomatic patients in northeastern Mexico with the rest of the country: its association with gastrointestinal disease. Arch. Med. Res. 2003;34:60-3.
  • Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, et al. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori associated gastroduodenal pathologies. Cancer Epidem. Biomar. 2008;17:2498- 2504.
  • López-Carrillo L, Torres-López J, Galván- Portillo M, et al. Helicobacter pylori-CagA seropositivity and nitrite and ascorbic acid food intake as predictors for Gastric Cancer. Eur. J. Cancer. 2004;40:1752-9.
  • Sicinschi LA, Lopez-Carrillo L, Camargo C, et al. Gastric cáncer risk in a Mexican Population: Role of Helicobacter pylori cagA positive infection and polymorphisms in interleukin-1 and -10 genes. Int. J. Cancer. 2006;118:649-57.
  • Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia. 2004;(6):449- 56.
  • Syrjanen K. A Panel of Serum Biomarkers (GastroPanel®) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. Anticancer Res. 2016;36 (10):5133-44.
  • Agréus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012;(47):136-47.
  • di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis 2008;(40):523-30.
  • Sipponen P, Harkonen M, Alanko A, et al. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002;(48):505-15.
  • Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy. 1997;(29):671-8.
  • Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol. 2001;(15):591-8.
  • Muszynski J, Ziolkowski B, et al. Gastritis- facts and doubts. Gastroenterol.Rev. 2016;11(4):286-295.
  • Abdo, J., Uscanga, L., Sobrino, S., Rivera, J., Huerta, F., Tamayo, J., MHSG. III. Consenso Mexicano sobre Helicobacter pylori. Rev. Gastroenterol. Méx. 2007;72:322-38.
  • Ayala G, Galván M, Chihu L, et al. Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. Microb. Drug Resist. 2011;20:1-5.
  • Garza-González E, Pérez- Pérez GI, Alanis-Aguilar O, et al. Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico. J. Antimicrob. Chemother.2002;14:342-5.
  • Garza-González E, Bosques-Padilla FJ, Tijerina-Menchaca R, et al. Characterization of Helicobacter pylori isolates from the north-eastern region of Mexico. Clin. Microbiol. Infect. 2004;10:41-45.
  • Morales-Espinosa R, González-Valencia G, Delgado G, et al. Susceptibility profile to common antimicrobials used for eradication of Helicobacter pylori infection in Mexico by agar dilution method. J. Chemotherapy. 2007;19:108-9.
  • Torres J, Camorlinga-Ponce M, Pérez- Pérez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J. Clin. Microbiol. 2001:39:2677-80.
  • Meining A, Bayerdorffer E, Muller P, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch. 1998;(432):311-4.
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.
  • Thrift AP, El-Serag HB. Burden of gastric cancer. Clin. Gastroenterol. Hepatol. 2019;18:534-42.
  • Pérez TE, Abdo FJ, Zavala SM, et al. Surgical treatment of gastric carcinoma at the Gastroenterology Service of the Hospital General de México. Rev Med Hosp Gen Mex. 2010;(73):9-15.
  • Martínez-Galindo MG, Zamarripa-Dorsey F, Carmona-Castañeda A, et al. Histopathologic characteristics of gastric adenocarcinoma in Mexican patients: a 10- year experience at the Hospital Juárez of Mexico. Rev Gastroenterol Mex 2015;80:21- 6.
  • Pérez TE, Abdo FJ, Zavala SM, et al. Surgical treatment of gastric carcinoma at the Gastroenterology Service of the Hospital General de México. Rev Med Hosp Gen Mex. 2010;73:9-15.
  • Moss SF. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology. 2017;3(2):183-91.
  • Sampieri CL, Mora M. Gastric cancer research in Mexico: A public health priority World J Gastroenterol. 2014 (20):4491-4502